Strontium ranelate : long-term efficacy over 8 years in postmenopausal osteoporotic women

in Arthritis and Rheumatism (2008, October), 58

Strontium ranelate antifracture study program : current data

in Osteoporosis International (2002), 13(S1), 153-154

Strontium ranelate decreases the level of urinary CTX-II in patients with knee osteoarthritis

in Arthritis and Rheumatism (2012), 64(S10), 111

Strontium ranelate decreases vertebral fracture risk whatever the level of pretreatment bone turnover markers

in Calcified Tissue International (2007, May), 80(Suppl.1), 29-30

Strontium ranelate demonstrates efficacy against hip fracture over 3 and 5 years in postmenopausal women at high risk of hip fracture

in Osteoporosis International (2008, April), 19(Suppl.1), 26-27

Strontium ranelate demonstrates vertebral and non-vertebral antifracture efficacy including hip fractures over 5 years in postmenopausal osteoporotic women

in Calcified Tissue International (2007, May), 80(Suppl.1), 47

Strontium Ranelate for the prevention of bone loss of early postmenopause

in Osteoporosis International (1998), 8(S3), 12

Strontium ranelate improves osteoarthritis symptoms compared to placebo in patients with knee OA: The SEKOIA study

in Osteoporosis International (2013, April), 24(Suppl.1), 49-51

Strontium ranelate in osteoporosis

in Current Pharmaceutical Design (2002), 8

Strontium ranelate in the prevention of osteoporotic fractures

in International Journal of Clinical Practice (2007), 61(2), 324-328

Osteoporosis results from a decrease in bone strength yielding increased susceptibility to fractures. Hip and spine fractures are a major cause of morbidity and mortality in the elderly population. With ... [more ▼]

Osteoporosis results from a decrease in bone strength yielding increased susceptibility to fractures. Hip and spine fractures are a major cause of morbidity and mortality in the elderly population. With an increasingly ageing world population, early prevention of bone loss is essential for adequate control of this condition. Strontium ranelate (PROTELOS (R)), an oral drug for postmenopausal osteoporosis, has been reported to decrease bone resorption and to stimulate bone formation. The efficacy in reducing vertebral fractures, non-vertebral including hip fractures, and the safety of strontium ranelate has been initially demonstrated over 3 years in the SOTI (Spinal Osteoporosis Therapeutic Intervention) and TROPOS (TReatment Of Peripheral OSteoporosis) studies and confirmed recently over up to 5 years. A preplanned analysis of a sub-group of patients aged 80 years and over showed that, currently, strontium ranelate is the only antiosteoporotic agent to reduce vertebral and non-vertebral fractures in this age group. [less ▲]